Compositions and methods for treatment of filovirus-mediated diseases

Abstract

The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.

What is claimed is: 
     
         1 . A method for treating a patient having a filovirus-mediated disease, said method comprising administering to said patient an agent selected from the agents listed in Table 1 in an amount that is effective to treat said patient. 
     
     
         2 . The method of  claim 1 , wherein said filovirus is Ebola virus or Marburg virus. 
     
     
         3 . The method of  claim 1 , said method further comprising administering a second agent selected from the agents listed in Table 1. 
     
     
         4 . The method of  claim 3 , wherein the first agent is aripiprazole. 
     
     
         5 . The method of  claim 4 , wherein the second agent is piperacetazine. 
     
     
         6 . The method of  claim 3 , wherein said agents are administered within twenty-four hours of each other. 
     
     
         7 . The method of  claim 3 , wherein said agents are administered within 1 hour of each other or substantially simultaneously. 
     
     
         8 . The method of  claim 1 , wherein said agent is administered orally, parenterally, systemically, topically, or inhalationally. 
     
     
         9 . The method of any of  claims 6 - 8 , wherein said first agent is aripiprazole and said second agent is piperacetazine. 
     
     
         10 . A composition comprising two or more agents selected from the group consisting of the agents of Table 1. 
     
     
         11 . The composition of  claim 10 , wherein said two or more agents are present in amounts that, when administered together to a patient with a filovirus-mediated disease, are effective to treat said patient. 
     
     
         12 . The composition of  claim 11 , wherein said filovirus is Ebola virus or Marburg virus. 
     
     
         13 . The composition of  claim 10 , wherein said two or more agents are aripiprazole and piperacetazine. 
     
     
         14 . A kit comprising:
 (a) an active agent selected from Table 1 or an analog thereof; and   (b) instructions for administering said agent to a patient having a filovirus-mediated disease.   
     
     
         15 . The kit of  claim 14 , wherein said filovirus is Ebola virus or Marburg virus. 
     
     
         16 . The kit of  claim 14 , further comprising a second active agent selected from Table 1 or an analog thereof. 
     
     
         17 . The kit of  claim 16 , wherein said first active agent is aripiprazole and said second active agent is piperacetazine. 
     
     
         18 . The kit of  claim 17 , wherein said first active agent and said second active agent are formulated separately.